Duke logo

UM1 10132 AZD1775 + Radiotherapy & Cisplatin in Cervical, Upper Vaginal, and Uterine Cancers - Clinical Trial

What is the Purpose of this Study?

We are doing this study to test how safe different doses of a study drug called AZD1775 are given with the standard radiotherapy and chemotherapy.

What is the Condition Being Studied?

Patients with cancer of the cervix, upper vaginal area or the uterus

Who Can Participate in the Study?

Adults with cancer of the cervix, upper vaginal area or the uterus who are planning to receive whole pelvic radiotherapy

Age Group
Adults

What is Involved?

If you join this study you will receive the study drug AZD1775 given with standard radiotherapy and cisplatin.
The dose of the drug will be different for every group participating in the study.
The dose will continue to increase for every group of study participants until side effects occur that require the dose to be lowered.

Study Details

Full Title
A Phase I Study of the Wee 1 kinase (Wee 1) inhibitor AZD1775 in combination with Radiotherapy and Cisplatin in Cervical, Upper Vaginal and Uterine Cancers
Principal Investigator
Medical Oncologist
Protocol Number
IRB:PRO00089135
NCT:NCT03345784
Phase
Phase I
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
studyrecruitment@duke.edu
or
919-681-5698